Increasing evidence demonstrate cholesterol metabolism and auxotrophy as targetable vulnerability in several cancers including pancreatic adenocarcinoma, glioblastoma, lymphoma and clear cell renal carcinoma, while key proteins facilitating cholesterol uptake like low-density lipoprotein receptor (LDLR), liver X receptor (LXR) and scavenger Receptor B1 (SCARB1) serve as ideal druggable targets to disrupt cholesterol metabolism (132–137). Here, LDLR is linked to clear cell renal carcinoma.